Pressrelease: InfiCure Bio signs agreement with two major international companies

The Umeå based life science company InfiCure Bio continues to take large steps in the global market by signing agreements with two major international companies. “The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio”, says [...]

Pressrelease: InfiCure Bio signs agreement with two major international companies2022-10-12T10:35:45+02:00

Pressrelease published on the CymaBay Seladelpar study!

Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse.  Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work with the NIF mouse, and comments on the positive results. You will find the full pressrelease here.

Pressrelease published on the CymaBay Seladelpar study!2021-12-08T12:38:55+01:00

Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!

We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in the NIF mouse in both liver and kidney. You will find the PDF of the poster "Seladelpar reduces established liver [...]

Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!2021-11-15T11:19:32+01:00
Go to Top